Deferoxamine mesylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for deferoxamine mesylate and what is the scope of freedom to operate?
Deferoxamine mesylate
is the generic ingredient in two branded drugs marketed by Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, West-ward Pharms Int, and Novartis, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.There are seven drug master file entries for deferoxamine mesylate. Six suppliers are listed for this compound.
Summary for deferoxamine mesylate
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 6 |
| NDAs: | 6 |
| Drug Master File Entries: | 7 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Clinical Trials: | 6 |
| Patent Applications: | 2,280 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price trends for deferoxamine mesylate |
| What excipients (inactive ingredients) are in deferoxamine mesylate? | deferoxamine mesylate excipients list |
| DailyMed Link: | deferoxamine mesylate at DailyMed |
Recent Clinical Trials for deferoxamine mesylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research | Phase 2 |
| Aditya S. Pandey, MD | Phase 2 |
| Beijing Ditan Hospital | Phase 1/Phase 2 |
Pharmacology for deferoxamine mesylate
| Drug Class | Iron Chelator |
| Mechanism of Action | Iron Chelating Activity |
Medical Subject Heading (MeSH) Categories for deferoxamine mesylate
US Patents and Regulatory Information for deferoxamine mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gland Pharma Ltd | DEFEROXAMINE MESYLATE | deferoxamine mesylate | INJECTABLE;INJECTION | 207384-002 | Sep 29, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Fresenius Kabi Usa | DEFEROXAMINE MESYLATE | deferoxamine mesylate | INJECTABLE;INJECTION | 078718-001 | Sep 15, 2009 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| West-ward Pharms Int | DEFEROXAMINE MESYLATE | deferoxamine mesylate | INJECTABLE;INJECTION | 078086-001 | May 30, 2007 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Gland Pharma Ltd | DEFEROXAMINE MESYLATE | deferoxamine mesylate | INJECTABLE;INJECTION | 207384-001 | Sep 29, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Hospira | DEFEROXAMINE MESYLATE | deferoxamine mesylate | INJECTABLE;INJECTION | 076019-002 | Mar 17, 2004 | AP | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for deferoxamine mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
